• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Emergency Classics

The SAVE trial: Captopril after acute MI reduces mortality and morbidity [Classics Series]

bys25qthea
December 4, 2013
in Emergency Classics, General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: CC/L. academia

1. Treating patients with captopril after acute MI with asymptomatic LV dysfunction reduces mortality from cardiovascular causes (i.e., atherosclerotic heart disease, progressive heart failure).

2. The captopril group experienced lower rates of hospitalization due to heart failure and recurrent MI.

Study Rundown: The SAVE trial was the first to demonstrate that treating patients with acute MI and asymptomatic LV dysfunction with ACE-I reduces morbidity and mortality. These benefits are thought to result from ACE-Is slowing the remodeling process that takes place after patients suffer MIs. These findings have since been replicated in other trials (e.g., TRACE trial), systematic reviews, and meta-analyses.

In patients suffering from an acute MI and asymptomatic LV dysfunction, early initiation of and continued treatment with captopril can significantly reduce cardiovascular mortality, hospitalization due to heart failure, and recurrent MIs.

Please click to read the study in NEJM

In-Depth [randomized controlled study]: The SAVE trial, first published in 1992 in NEJM, is a randomized controlled trial that sought to explore the effect of captopril on mortality in patients suffering from acute myocardial infarction (MI) and asymptomatic left ventricular (LV) dysfunction. In previous animal studies, angiotensin converting enzyme inhibitors (ACE-Is) like captopril were shown to delay ventricular remodeling, and help preserve function after MI.

RELATED REPORTS

Clopidogrel monotherapy is superior to aspirin monotherapy for chronic maintenance after percutaneous coronary intervention

#VisualAbstract: Polypill plus aspirin treatment decreases cardiovascular event incidence

Multiple sclerosis patient at higher risk for cerebrovascular and cardiovascular disease

The trial was conducted at 45 centres across North America. A total of 2,231 patients took part in the study and were randomized to receive either captopril or placebo. Patients were followed for a minimum of 2 years, though mean follow-up was 42 months. Treatment with captopril or placebo was initiated 3-16 days after MI (mean of 11 days). Patients randomized to receive captopril experienced significantly reduced all-cause mortality and mortality from cardiovascular causes compared to the placebo group. Specifically, captopril was associated with significant reductions in mortality from atherosclerotic heart disease and progressive heart failure. Moreover, the captopril group demonstrated significant decreases in hospitalizations because of heart failure and recurrent MIs, compared to placebo.

By Adrienne Cheung, Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: captoprilheart attackMISAVE Trial
Previous Post

Mild hypothermia improves neurological outcome after cardiac arrest [Classics Series]

Next Post

Rates of multiple births and multiple embryo IVF procedures have decreased in the past decade

RelatedReports

Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Clopidogrel monotherapy is superior to aspirin monotherapy for chronic maintenance after percutaneous coronary intervention

July 7, 2021
#VisualAbstract: Polypill plus aspirin treatment decreases cardiovascular event incidence
Chronic Disease

#VisualAbstract: Polypill plus aspirin treatment decreases cardiovascular event incidence

April 21, 2021
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Cardiology

Multiple sclerosis patient at higher risk for cerebrovascular and cardiovascular disease

May 31, 2020
Classics Series, Landmark Trials in Medicine
General Medicine Classics

The POISE trial: Perioperative use of beta-blockers [Classics Series]

June 12, 2020
Next Post
Assisted conception not associated with increased pediatric cancer risk

Rates of multiple births and multiple embryo IVF procedures have decreased in the past decade

Imaging biomarkers may improve prediction of aortic valve stenosis

Imaging biomarkers may improve prediction of aortic valve stenosis

Duloxetine reduces neuropathic pain in chemotherapy patients

Longer preoperative treatment of advanced pancreatic cancer may extend survival

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Newborn screening for cystic fibrosis improves nutritional outcomes
  • BNT162b2 vaccine reduces rates of COVID-19 omicron variant infection in children
  • Non-contrast CT sensitive and specific for kidney stones [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.